Merck & Co, developer of the new cervical-cancer vaccine, is funding efforts to pass state laws requiring girls as young as 11 to receive the vaccine. At least 18 states are debating whether to require Merck’s vaccine for girls. The pharmaceutical company has funneled money through an advocacy group.
This is the same pharmaceutical company who suffered many financial setbacks when Vioxx was pulled off the market for its harmful side effects. While the idea of potentially eliminating a cancer is undoubtedly a great goal, the manner in which the pharmaceutical company is attempting to benefit is worrisome.
For the full article.